Oxiracetam – (62613-82-5)

Oxiracetam, a nootropic drug of the racetam family, is known for its cognitive-enhancing properties and mild stimulant effects. It has been studied for its potential benefits in improving memory, attention, and learning, particularly in individuals with cognitive impairments.

Clinical trials have shown mixed results regarding its efficacy in treating dementia. While some studies indicate beneficial effects in patients with mild to moderate dementia, including improvements in logical performance, attention, and memory, others, such as a trial involving Alzheimer’s patients, have not demonstrated significant cognitive improvements.

Oxiracetam’s neuroprotective properties and ability to modulate inflammatory responses make it a subject of interest in the study of central nervous system diseases. It has been shown to inhibit amyloid beta-induced cell activation and improve cognitive impairment in animal models of chronic cerebral ischemia.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Oxiracetam
https://www.medchemexpress.com/Oxiracetam.html
https://www.medkoo.com/products/16301
https://go.drugbank.com/drugs/DB13601
https://pubmed.ncbi.nlm.nih.gov/1444879/
https://pubmed.ncbi.nlm.nih.gov/2521069/